| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Comprehensive RNA sequencing showed that mRNA level expression of smooth muscle protein 22-alpha (SM22a), annexin A2 (ANXA2), CCN2, IGFBP3, and CCN1 were up-regulated, whereas those of the TP53 was down-regulated by treatment with jiadifenolide. In silico molecular network analysis showed that the up-regulated mRNA level expression of CCN, CCN1, CCN2, SM22a, ANXA2, and IGFBP3 genes were related to the regulation of SMAD, SMAD1, SMAD2, SMAD3, nuclear factor-κB (NF-κB), and STAT3 or p53. RT-qPCR showed that expression levels of CCN1, CCN2, CCN6, SM22a, and AXNA2 mRNA were significantly up-regulated in jiadifenolide-treated cells. These results showed that jiadifenolide activates CCN signaling via up-regulating the mRNA level expression of the CCN family members CCN1, CCN2, and CCN6, and CCN2 gene expression. CCN2 protein promoted neuronal dendritic outgrowth and increased neuronal cell numbers and increased phosphorylation of p44/42 MAPK protein in human neuronal precursor cells.
|
